{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:52:17Z","timestamp":1778543537715,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bonr.2021.101098","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T13:33:35Z","timestamp":1623072815000},"page":"101098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes"],"prefix":"10.1016","volume":"15","author":[{"given":"Konstantin","family":"Byrgazov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annica J.","family":"Rasmusson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claes","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Slipicevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Gullbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e5kan","family":"Melhus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e5rten","family":"Frykn\u00e4s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bonr.2021.101098_bb0005","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bonr.2021.101098_bb0010","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1172\/JCI35711","article-title":"NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism","volume":"118","author":"Aliprantis","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bonr.2021.101098_bb0015","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bonr.2021.101098_bb0020","doi-asserted-by":"crossref","first-page":"8772","DOI":"10.1093\/nar\/gkw615","article-title":"Human CDK18 promotes replication stress signaling and genome stability","volume":"44","author":"Barone","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bonr.2021.101098_bb0025","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bone.2007.09.046","article-title":"NHA-oc\/NHA2: a mitochondrial cation-proton antiporter selectively expressed in osteoclasts","volume":"42","author":"Battaglino","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2021.101098_bb0030","doi-asserted-by":"crossref","first-page":"21105","DOI":"10.1073\/pnas.1111919109","article-title":"Human monocytes are severely impaired in base and DNA double-strand break repair that renders them vulnerable to oxidative stress","volume":"108","author":"Bauer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bonr.2021.101098_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039956","article-title":"Human monocytes undergo excessive apoptosis following temozolomide activating the ATM\/ATR pathway while dendritic cells and macrophages are resistant","volume":"7","author":"Bauer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bonr.2021.101098_bb0040","doi-asserted-by":"crossref","first-page":"103037","DOI":"10.1016\/j.dnarep.2020.103037","article-title":"Impaired DNA repair in mouse monocytes compared to macrophages and precursors","volume":"98","author":"Berte","year":"2020","journal-title":"DNA Repair (Amst.)"},{"key":"10.1016\/j.bonr.2021.101098_bb0045","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bonr.2021.101098_bb0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/0008-5472.CAN-06-3712","article-title":"Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents","volume":"67","author":"Briegert","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bonr.2021.101098_bb0055","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nm.1860","article-title":"Brain-type creatine kinase has a crucial role in osteoclast-mediated bone resorption","volume":"14","author":"Chang","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.bonr.2021.101098_bb0060","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinforma."},{"key":"10.1016\/j.bonr.2021.101098_bb0065","first-page":"6109","article-title":"DNA topoisomerase II alpha expression is associated with alkylating agent resistance","volume":"55","author":"Eder","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.bonr.2021.101098_bb0070","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1091\/mbc.e13-07-0363","article-title":"Comparative transcriptomics reveals RhoE as a novel regulator of actin dynamics in bone-resorbing osteoclasts","volume":"25","author":"Georgess","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bonr.2021.101098_bb0075","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.yexcr.2007.10.021","article-title":"Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA)","volume":"314","author":"Hecht","year":"2008","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bonr.2021.101098_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013305","article-title":"Retinoic acid increases proliferation of human osteoclast progenitors and inhibits RANKL-stimulated osteoclast differentiation by suppressing RANK","volume":"5","author":"Hu","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bonr.2021.101098_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207255","article-title":"MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors","volume":"13","author":"Juric","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bonr.2021.101098_bb0090","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/jcb.20835","article-title":"Secretion of tartrate-resistant acid phosphatase by osteoclasts correlates with resorptive behavior","volume":"98","author":"Kirstein","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bonr.2021.101098_bb0095","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/002215540104900312","article-title":"Expression and distribution of tartrate-resistant purple acid phosphatase in the rat nervous system","volume":"49","author":"Lang","year":"2001","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.bonr.2021.101098_bb0100","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41598-017-00923-0","article-title":"MMP9 integrates multiple immunoregulatory pathways that discriminate high suppressive activity of human mesenchymal stem cells","volume":"7","author":"Lavini-Ramos","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bonr.2021.101098_bb0105","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Lee","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.bonr.2021.101098_bb0110","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/nprot.2008.114","article-title":"The fluorometric microculture cytotoxicity assay","volume":"3","author":"Lindhagen","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bonr.2021.101098_bb0115","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.4049\/jimmunol.0903789","article-title":"The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule a independent of a disintegrin and metalloproteinases","volume":"184","author":"Liu","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.bonr.2021.101098_bb0120","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.blre.2016.04.002","article-title":"Myeloid-derived suppressor cells: the green light for myeloma immune escape","volume":"30","author":"Malek","year":"2016","journal-title":"Blood Rev."},{"key":"10.1016\/j.bonr.2021.101098_bb0125","first-page":"115","article-title":"Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bonr.2021.101098_bb0130","first-page":"8","article-title":"Multiple myeloma and bone: the fatal interaction","author":"Marino","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bonr.2021.101098_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.bonr.2021.101098_bb0140","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bonr.2021.101098_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103120","article-title":"Melflufen: a peptide-drug conjugate for the treatment of multiple myeloma","volume":"9","author":"Mateos","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bonr.2021.101098_bb0150","first-page":"11729","article-title":"Human RAD51 paralogue RAD51C fosters repair of alkylated DNA by interacting with the ALKBH3 demethylase","volume":"47","author":"Mohan","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bonr.2021.101098_bb0155","first-page":"1","article-title":"Melflufen for relapsed and refractory multiple myeloma","author":"Oriol","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.bonr.2021.101098_bb0160","article-title":"Multiple myeloma\/hypercalcemia","volume":"9","author":"Oyajobi","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bonr.2021.101098_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30044-2","article-title":"Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study","volume":"7","author":"Richardson","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.bonr.2021.101098_bb0170","article-title":"Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma","author":"Richardson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bonr.2021.101098_bb0175","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/bies.20473","article-title":"Extraneuronal roles of cyclin-dependent kinase 5","volume":"28","author":"Rosales","year":"2006","journal-title":"Bioessays"},{"key":"10.1016\/j.bonr.2021.101098_bb0180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00774-006-0725-9","article-title":"Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood","volume":"25","author":"Sorensen","year":"2007","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bonr.2021.101098_bb0185","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.18632\/oncotarget.13856","article-title":"In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia","volume":"8","author":"Strese","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bonr.2021.101098_bb0190","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3389\/fimmu.2018.01822","article-title":"Osteoclast immunosuppressive effects in multiple myeloma: role of programmed cell death ligand 1","volume":"9","author":"Tai","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bonr.2021.101098_bb0195","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bonr.2021.101098_bb0200","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bonr.2021.101098_bb0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bonr.2021.101098_bb0210","doi-asserted-by":"crossref","first-page":"66641","DOI":"10.18632\/oncotarget.18420","article-title":"Melflufen - a peptidase-potentiated alkylating agent in clinical trials","volume":"8","author":"Wickstrom","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bonr.2021.101098_bb0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2010.08141.x","article-title":"Advances in the understanding of myeloma bone disease and tumour growth","volume":"149","author":"Yaccoby","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bonr.2021.101098_bb0220","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bonr.2021.101098_bb0225","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.leu.2405048","article-title":"Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts","volume":"22","author":"Yaccoby","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bonr.2021.101098_bb0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clim.2018.10.013","article-title":"SLAMF6 in health and disease: implications for therapeutic targeting","volume":"204","author":"Yigit","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bonr.2021.101098_bb0235","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-18-0664","article-title":"SLAMF6 as a regulator of exhausted CD8(+) T cells in cancer","volume":"7","author":"Yigit","year":"2019","journal-title":"Cancer Immunol. Res."}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187221003545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187221003545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:26:17Z","timestamp":1762446377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187221003545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":47,"alternative-id":["S2352187221003545"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2021.101098","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2021.101098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101098"}}